ReviewCureus2022
Atrial Fibrillation in Chronic Kidney Disease: An Overview.
Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Efficacy and safety of novel anticoagulant therapies in patients with chronic kidney disease-a systematic review and meta-analysis.Journal of nephrology · 2025Pooled it
- Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced CKD Not Requiring Dialysis.JAMA network open · 2026Article
- Scoping review of apixaban and rivaroxaban dosing for atrial fibrillation and venous thromboembolism in advanced chronic kidney disease.International journal of clinical pharmacy · 2026Article
- Development and internal validation of an interpretable machine-learning model for identifying comorbid atrial fibrillation in patients with diabetic kidney disease.Frontiers in clinical diabetes and healthcare · 2026Article
- Association of Renal Impairment Severity with Surgical Outcomes in Patients with Infective Endocarditis.Current cardiology reviews · 2026Article
- Clonal Hematopoiesis and Cardiovascular Events in Patients with ESKD on Hemodialysis: Results from the VIVALDI Study.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- Novel predictive role of glomerular filtration rate in atrial fibrillation development among chronic heart failure patients.BMC cardiovascular disorders · 2025Article
- Systemic anticoagulation in progressive chronic kidney disease and atrial fibrillation.The Journal of international medical research · 2025Observational
- The Impact of Weight Categories on the Association Between Atrial Fibrillation/Flutter and Known Risk Factors: A Nationwide Inpatient Data Analysis.Journal of clinical medicine · 2025Article
- Unveiling the role of sex in the metabolism of indoxyl sulfate and apixaban.Scientific reports · 2025Article
- Should We Still Feel Reluctant About Prescribing Rivaroxaban for Advanced Chronic Kidney Disease?JACC. Advances · 2024Article
- Clinical outcomes and predictors of long-term mortality, hemorrhagic and thromboembolic events in atrial fibrillation patients at different stages of chronic kidney disease: The CRAFT trial.International journal of cardiology. Heart & vasculature · 2023Article
- Standard Modifiable Cardiovascular Risk Factors and Prognostic Outcomes in Non-Valvular Atrial Fibrillation Patients on Oral Anticoagulants.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is a condition that can be caused due to any etiology leading to structural damage to the kidney, which can be measured by a decrease in estimated glomerular filtration rate (eGFR) and the presence of damage biomarkers for more than three months. This article has discussed the causal relationship between atrial fibrillation (AF) and CKD, a few of them being inflammation, renin-angiotensin-aldosterone system (RAAS) activation, anemia, and uremia associated with CKD. This review mentioned the clinical impact of the presence of AF in CKD patients. The presence of AF in CKD patients aggravates the renal dysfunction, which in turn adds to the generation of AF. This article explores the various pharmacological and interventional treatment modalities, including antiarrhythmics, anticoagulants, and cardiac ablation, and their complications, leading to restricted usage in CKD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.